Protagenic Therapeutics, Inc. Files 10-K/A Amendment

TL;DR

<b>Protagenic Therapeutics, Inc. filed a 10-K/A amendment on April 24, 2024, for the fiscal year ending December 31, 2023.</b>

AI Summary

Protagenic Therapeutics, Inc.\new (PTIXW) filed a Amended Annual Report (10-K/A) with the SEC on April 24, 2024. Protagenic Therapeutics, Inc. filed a 10-K/A amendment on April 24, 2024. The filing covers the fiscal year ending December 31, 2023. The company was formerly known as Atrinsic, Inc. and NEW MOTION, INC. The filing includes data related to common stock, preferred stock, and warrants. Financial data points for 2021, 2022, and 2023 are referenced.

Why It Matters

For investors and stakeholders tracking Protagenic Therapeutics, Inc.\new, this filing contains several important signals. This amended filing provides updated financial and operational information for the fiscal year 2023, crucial for investors to assess the company's current standing. The inclusion of historical financial data from 2021 and 2022 allows for year-over-year comparisons, aiding in the analysis of trends and performance.

Risk Assessment

Risk Level: — Protagenic Therapeutics, Inc.\new shows moderate risk based on this filing. The filing is an amendment (10-K/A) to a previous filing, indicating potential corrections or additions to previously reported information, but the content itself does not reveal immediate high-risk factors.

Analyst Insight

Review the specific amendments made in this 10-K/A filing to understand any changes in financial reporting or disclosures for the fiscal year 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-24 — Filing Date (Date of 10-K/A filing)
• 2023-01-01 — Fiscal Year Start (Reporting period)

Key Players & Entities

• Protagenic Therapeutics, Inc. (company) — Filer name
• Atrinsic, Inc. (company) — Former company name
• NEW MOTION, INC. (company) — Former company name
• 2024-04-24 (date) — Filing date
• 2023-12-31 (date) — Fiscal year end

FAQ

Industry Context

Protagenic Therapeutics operates in the pharmaceutical preparations industry.

Regulatory Implications

The filing is a 10-K/A, an amendment to an annual report, filed under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the specific changes and additions made in the 10-K/A filing.
2. Compare the 2023 financial data with previous years (2021, 2022) for trend analysis.
3. Investigate the company's history of name changes to understand its corporate evolution.

Key Dates

• 2024-04-24: 10-K/A Filing — Amendment filed for the fiscal year ending 2023-12-31.

Year-Over-Year Comparison

This is an amended filing (10-K/A) for the fiscal year 2023, indicating updates or corrections to previously submitted information.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 , PTIX Nasdaq Capital Market Commo
• $2.03 — eported on the Nasdaq Capital Market of $2.03 was approximately $ 8,791,847 . As of
• $0 — he registrant's common stock, par value $0.0001, issued and outstanding. DOCUMEN

Filing Documents

• form10-ka.htm (10-K/A) — 1480KB
• ex32-1.htm (EX-32.1) — 8KB
• form10-k_001.jpg (GRAPHIC) — 22KB
• form10-k_002.jpg (GRAPHIC) — 12KB
• form10-k_003.jpg (GRAPHIC) — 20KB
• form10-k_004.jpg (GRAPHIC) — 17KB
• 0001493152-24-015739.txt (&nbsp;) — 5395KB
• ptix-20231231.xsd (EX-101.SCH) — 34KB
• ptix-20231231_cal.xml (EX-101.CAL) — 46KB
• ptix-20231231_def.xml (EX-101.DEF) — 177KB
• ptix-20231231_lab.xml (EX-101.LAB) — 347KB
• ptix-20231231_pre.xml (EX-101.PRE) — 272KB
• form10-ka_htm.xml (XML) — 568KB

Business

Business 6 Item 1A Risk Factors 20 Item 1B Unresolved Staff Comments 41 Item 1C Cybersecurity 41 Item 2

Properties

Properties 41 Item 3

Legal Proceedings

Legal Proceedings 41 Item 4 Mine Safety Disclosures 41 PART II 42 Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 42 Item 6 [Reserved] 42 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 42 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 45 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 45 Item 9A

Controls and Procedures

Controls and Procedures 46 Item 9B Other Information 47 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 48 PART III 48 Item 10 Directors, Executive Officers and Corporate Governance 48 Item 11

Executive Compensation

Executive Compensation 54 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 56 Item 13 Certain Relationships and Related Transactions, and Director Independence 65 Item 14 Principal Accountant Fees and Services 67 PART IV 67 Item 15 Exhibits and Financial Statement Schedules 67

SIGNATURES

SIGNATURES 70 2 EXPLANATORY NOTE Protagenic Therapeutics, Inc. (the "Company") is filing this Amendment No. 1 (this "Amendment") to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on April 1, 2023 (the "Original Filing") to correct an inadvertent error in the Original Filing. Exhibit 32.1 (Certification Pursuant To 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002) was inadvertently omitted from the filed version of the Original Filing. The Company is filing this Amendment solely for the purpose of including Exhibit 32.1. No attempt has been made in this Amendment to otherwise modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the Original Filing (i.e., those events occurring after April 1, 2024) or modify or update those disclosures that may be affected by subsequent events. Such subsequent matters are addressed in subsequent reports filed with the SEC. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company's other filings with the SEC. 3 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievement

View Full Filing

View this 10-K/A filing on SEC EDGAR